NASDAQ:PZRX PhaseRx (PZRX) Stock Price, News & Analysis → Your 'AI Income Playbook' Awaits... (From The Oxford Club) (Ad) Free PZRX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.28▼$0.3450-Day Range$0.28▼$0.2852-Week Range$0.22▼$1.95Volume1.05 million shsAverage Volume1.24 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get PhaseRx alerts: Email Address Ad Porter & CompanyTop-Secret Government Project RevealedDetails a top-secret program for taking America’s most critical technology mainstream. And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. About PhaseRxPhaseRx, Inc. operates as a biopharmaceutical company that develops a portfolio of mRNA products to correct inherited, life-threatening liver diseases in children. Its product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency; argininosuccinate lyase deficiency; and argininosuccinate synthetase deficiency. The company was founded by Robert W. Overell, Patrick S. Stayton, Allan S. Hoffman, Oliver W. Press, and Paul H. Johnson on March 9, 2006 and is headquartered in Seattle, WA.Read More Ad Porter & CompanyTop-Secret Government Project RevealedDetails a top-secret program for taking America’s most critical technology mainstream. And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. PZRX Stock News HeadlinesApril 14, 2024 | morningstar.comPowszechny Zaklad Ubezpieczen SA PZUJune 21, 2023 | investing.comNimbus Group AB (BOAT)May 15, 2023 | investing.comPhaseRx (PZRXQ) Earnings Dates & ReportsSeptember 16, 2022 | investing.comTongwei Co Ltd (600438)September 13, 2022 | investing.comDeNA Co Ltd (2432)See More Headlines Receive PZRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PhaseRx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/09/2017Today6/15/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PZRX CUSIPN/A CIK1429386 Webphaserx.com Phone(206) 805-6300FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesSteven H. Gillis Ph.D. (Age 63)Independent Chairman of the Board Robert W. Overell Ph.D. (Age 61)President, Chief Executive Officer, Principal Accounting Officer, Secretary, Director Sean Monahan Ph.D.Vice President - ChemistryMary G. Prieve Ph.D.Vice President - BiologyGordon Brandt M.D. (Age 57)Chief Medical Officer James D. WatsonHead of Corporate DevelopmentPaul H. Johnson Ph.D. (Age 73)Director Brian G. Atwood (Age 64)Independent Director Michelle Renee Griffin (Age 51)Independent Director Peggy V. Phillips (Age 63)Independent Director More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors PZRX Stock Analysis - Frequently Asked Questions How were PhaseRx's earnings last quarter? PhaseRx, Inc. (NASDAQ:PZRX) released its earnings results on Thursday, November, 9th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.14. What other stocks do shareholders of PhaseRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseRx investors own include Avid Bioservices (CDMO), Immutep (IMMP), Arbutus Biopharma (ABUS), Allena Pharmaceuticals (ALNA), Biocept (BIOC), Eleven Biotherapeutics (EBIO), Net Element (NETE), OHR Pharmaceutical (OHRP), When did PhaseRx IPO? PhaseRx (PZRX) raised $18 million in an IPO on Wednesday, May 18th 2016. The company issued 3,700,000 shares at a price of $5.00 per share. Laidlaw & Company (UK) Ltd. and Roth Capital Partners acted as the underwriters for the IPO. This page (NASDAQ:PZRX) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersPresident KamalaThe sneaky (yet 100% legal) way for Obama to return to power The ONLY way Democrats can keep the White Hous...Stansberry Research | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredTime is Running Out - June 25th Deadline Approaching!Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRIL...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhaseRx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PhaseRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.